Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
This is a phase II clinical trial of the combination of carboplatin, eribulin, and Veliparib.
Breast Cancer Stage IV|Ovarian Cancer|BRCA1 Mutation|BRCA2 Mutation
DRUG: Carboplatin|DRUG: Eribulin|DRUG: Veliparib
Incidence, nature and severity of adverse events and serious adverse events, graded according to NCI - Common Toxicity Criteria for Adverse Events version (4.03), Graded according to NCI - Common Toxicity Criteria for Adverse Events version (4.03), Approximately 1.5 years|Tumor response assessed using RECIST 1.1 guidelines, Response will be assessed in this study via physical exam and imaging., Measured every 6 weeks for 21 day cycles for the duration of study treatment, estimated to be less than one year
This is a Phase II, non-randomized, open-label, Clinical Trial on the Combination of Carboplatin, Eribulin, and Veliparib in Patients with BRCA-related Cancers.